Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research

The David H. Koch Institute for Integrative Cancer Research at MIT both transforms and transcends the MIT Center for Cancer Research (CCR). Founded in 1974 by Nobel Laureate and MIT Professor Salvador Luria, CCR has made enormous contributions to the field of cancer research, including: identified the molecules that led to two of the first FDA-approved molecularly targeted anti-cancer drugs, Herceptin? (1998) and Gleevec? (2001); isolated the first human cancer genes; discovered extracellular matrix components and their receptors, which play a critical role in metastasis; contributed to the sequencing of the human genome; and developed novel materials for sustained delivery of anti-cancer drugs.

The Koch Institute remains one of only eight National Cancer Institute-designated basic research centers in the US. Our faculty have earned the most prestigious national and international science honors: five current and former faculty have been awarded the Nobel Prize; 14 current faculty are members of the National Academy of Sciences; 6 current and former faculty have been awarded the National Medal of Science; 5 current faculty are Howard Hughes Medical Institute Investigators.

  1. [MSFELLOW22] Mazumdar-Shaw International Oncology Fellow (offers accepted)
  2. [MSFELLOW23] Mazumdar-Shaw International Oncology Fellow

(2 positions listed)